Psoriasis
Conditions
Keywords
Multicenter study
Brief summary
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.
Interventions
None listed
Sponsors
Veeda Clinical Research
AbbVie (prior sponsor, Abbott)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients \> or = 18 years * Patient with chronic plaque psoriasis * Patient newly initiated on Humira * Patient compliant with Humira Summary of Product Characteristics * Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis * Patient has signed informed consent
Exclusion criteria
* Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira * Patients not willing to sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adalimumab Treatment Retention Status | Month 24/ Early Termination visit | Percentage of participants with an adalimumab treatment status of continuous, early intermittent, late intermittent, permanently discontinued, or other. Continuous=initiated on adalimumab, had no treatment interruption period, still on treatment at study termination, and completed the study. Early intermittent=initiated on adalimumab 40 mg, treated every other week (EOW) for \< 112 days (16 weeks) after initiation of treatment, with afterwards ≥ 1 treatment interruption period of ≥ 70 consecutive days, on treatment at study termination, and completed the study. Late intermittent=initiated on adalimumab 40 mg, treated EOW for ≥ 112 days (16 weeks) after initiation of treatment, with afterwards ≥ 1 treatment interruption period of at least 70 consecutive days, on treatment at study termination, and completed the study. Permanently discontinued=received ≥ 1 dose of adalimumab and stopped adalimumab treatment permanently. Other=participants not belonging to any of the previous groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Percentage of participants who achieved ≥ 50%, 75%, 90% or 100% reduction (improvement) from Baseline in PASI score (PASI50, PASI75, PASI90, PASI100). Four anatomic sites (head, upper extremities, trunk, and lower extremities) were assessed for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination. The severity of each sign was assessed using a 5-point scale: 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. PASI percentage improvement=100\*(PASI score at Baseline - score at follow-up visit) / PASI score at Baseline. For the purpose of analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based on the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Clinical psoriasis evaluations by the investigator of percentage of affected BSA. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (obs.; up to 24 months) | The PGA was an evaluation of a participant's psoriasis on a 6-point scale: clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5), which were then regrouped into the 2 categories Clear/Minimal or Mild/Moderate/Severe/Very Severe (M/Md/S/VS), and presented as the percentage of participants in each. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | DLQI score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each question are: very much (3), a lot (2), a little (1), or not at all (0). The total DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows, based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Four anatomic sites (head, upper extremities, trunk, and lower extremities) were assessed with PASI for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination. The severity of each sign was assessed using a 5-point scale: 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. PASI percentage improvement=100\*(PASI score at Baseline - score at follow-up visit) / PASI score at Baseline. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Absenteeism, presented as the mean percentage of work time missed due to psoriasis (as reported on the WPAI), and calculated as: 100\*number of hours of work missed due to psoriasis / (number of hours of work missed due to psoriasis + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Presenteeism (the extent to which psoriasis decreased productivity) is presented as the mean percentage of impairment while working due to psoriasis, and calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | The mean percentage of TWPI due to psoriasis (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which psoriasis decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to psoriasis + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | Activity impairment due to psoriasis (the extent to which psoriasis affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
| DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months) | DLQI is a participant-reported outcome consisting of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot (score of 2), a little (score of 1), or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect. Follow-up visits were classified into time windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730). |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Participants Treated With Adalimumab Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment was initiated. All medications were prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria. | 191 |
| Total | 191 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 24 |
| Overall Study | Other | 4 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | Participants Treated With Adalimumab |
|---|---|
| Age, Continuous | 44.9 years STANDARD_DEVIATION 12.1 |
| Sex: Female, Male Female | 58 Participants |
| Sex: Female, Male Male | 133 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 67 / 191 |
| serious Total, serious adverse events | 19 / 191 |
Outcome results
Primary
Adalimumab Treatment Retention Status
Percentage of participants with an adalimumab treatment status of continuous, early intermittent, late intermittent, permanently discontinued, or other. Continuous=initiated on adalimumab, had no treatment interruption period, still on treatment at study termination, and completed the study. Early intermittent=initiated on adalimumab 40 mg, treated every other week (EOW) for \< 112 days (16 weeks) after initiation of treatment, with afterwards ≥ 1 treatment interruption period of ≥ 70 consecutive days, on treatment at study termination, and completed the study. Late intermittent=initiated on adalimumab 40 mg, treated EOW for ≥ 112 days (16 weeks) after initiation of treatment, with afterwards ≥ 1 treatment interruption period of at least 70 consecutive days, on treatment at study termination, and completed the study. Permanently discontinued=received ≥ 1 dose of adalimumab and stopped adalimumab treatment permanently. Other=participants not belonging to any of the previous groups.
Time frame: Month 24/ Early Termination visit
Population: Intention to Treat (ITT) set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participants Treated With Adalimumab | Adalimumab Treatment Retention Status | Continuous | 44.0 percentage of participants |
| Participants Treated With Adalimumab | Adalimumab Treatment Retention Status | Early intermittent | 2.6 percentage of participants |
| Participants Treated With Adalimumab | Adalimumab Treatment Retention Status | Late intermittent | 8.4 percentage of participants |
| Participants Treated With Adalimumab | Adalimumab Treatment Retention Status | Permanently discontinued | 38.7 percentage of participants |
| Participants Treated With Adalimumab | Adalimumab Treatment Retention Status | Other | 6.3 percentage of participants |
Secondary
Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status
DLQI score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each question are: very much (3), a lot (2), a little (1), or not at all (0). The total DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows, based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 1.44 units on a scale | Standard Deviation 3.21 |
| Participants Treated With Adalimumab | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 3.41 units on a scale | Standard Deviation 4.69 |
| Participants Treated With Adalimumab | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 12.48 units on a scale | Standard Deviation 7.18 |
| Participants Treated With Adalimumab | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 1.56 units on a scale | Standard Deviation 3.19 |
| Participants Treated With Adalimumab | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 1.51 units on a scale | Standard Deviation 2.33 |
| Participants Treated With Adalimumab: Early Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 0.33 units on a scale | Standard Deviation 0.58 |
| Participants Treated With Adalimumab: Early Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 7.40 units on a scale | Standard Deviation 3.51 |
| Participants Treated With Adalimumab: Early Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 13.80 units on a scale | Standard Deviation 6.72 |
| Participants Treated With Adalimumab: Early Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 7.40 units on a scale | Standard Deviation 3.51 |
| Participants Treated With Adalimumab: Early Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 18.00 units on a scale | — |
| Participants Treated With Adalimumab: Late Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 3.53 units on a scale | Standard Deviation 5.8 |
| Participants Treated With Adalimumab: Late Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 5.50 units on a scale | Standard Deviation 5.17 |
| Participants Treated With Adalimumab: Late Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 5.13 units on a scale | Standard Deviation 5.18 |
| Participants Treated With Adalimumab: Late Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 3.42 units on a scale | Standard Deviation 3.03 |
| Participants Treated With Adalimumab: Late Intermittent | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 12.27 units on a scale | Standard Deviation 6.13 |
| Participants Treated With Adalimumab: Permanently Discontinued | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 6.94 units on a scale | Standard Deviation 6.54 |
| Participants Treated With Adalimumab: Permanently Discontinued | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 12.97 units on a scale | Standard Deviation 7.02 |
| Participants Treated With Adalimumab: Permanently Discontinued | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 5.38 units on a scale | Standard Deviation 5.89 |
| Participants Treated With Adalimumab: Permanently Discontinued | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 4.32 units on a scale | Standard Deviation 5.42 |
| Participants Treated With Adalimumab: Permanently Discontinued | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 6.08 units on a scale | Standard Deviation 6.74 |
| Participants Treated With Adalimumab: Other | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 10.00 units on a scale | Standard Deviation 9 |
| Participants Treated With Adalimumab: Other | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 12.08 units on a scale | Standard Deviation 7.35 |
| Participants Treated With Adalimumab: Other | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 8.25 units on a scale | Standard Deviation 8.4 |
| Participants Treated With Adalimumab: Other | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 7.13 units on a scale | Standard Deviation 9.51 |
| Participants Treated With Adalimumab: Other | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 3.33 units on a scale | Standard Deviation 6.31 |
| Participants Treated With Adalimumab: All Participants | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=80, 5, 15, 70, 12, 182 | 12.66 units on a scale | Standard Deviation 6.97 |
| Participants Treated With Adalimumab: All Participants | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=71, 5, 14, 44, 3, 137 | 3.18 units on a scale | Standard Deviation 4.79 |
| Participants Treated With Adalimumab: All Participants | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=73, 3, 15, 61, 8, 160 | 4.30 units on a scale | Standard Deviation 5.62 |
| Participants Treated With Adalimumab: All Participants | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=82, 5, 15, 74, 12, 188 | 4.21 units on a scale | Standard Deviation 5.87 |
| Participants Treated With Adalimumab: All Participants | Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=68, 1, 12, 47, 6, 134 | 3.79 units on a scale | Standard Deviation 5.24 |
Secondary
DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status
DLQI is a participant-reported outcome consisting of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot (score of 2), a little (score of 1), or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect. Follow-up visits were classified into time windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 41.3 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 1.5 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 16.9 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 5.0 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 76.1 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 2.4 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 13.8 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 6.1 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 50.7 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 12.5 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 18.3 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 26.0 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 16.4 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 73.2 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 5.5 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 1.4 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 69.1 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 2.8 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 26.5 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 27.5 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 4.2 percentage of participants |
| Participants Treated With Adalimumab | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 2.9 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 6.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 21.4 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 21.4 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 6.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 46.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 25.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 35.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 41.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 46.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 20.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 6.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 6.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 6.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 21.4 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 47.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 2.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 15.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 15.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 51.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 14.3 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 27.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 34.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 19.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 16.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 1.6 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 31.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 17.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 19.1 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 27.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 4.3 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 15.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 27.3 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 6.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 2.3 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 37.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 14.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 27.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 16.2 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 4.1 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 16.7 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 50.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 16.7 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 25.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 8.3 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 50.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 25.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 25.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 16.7 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 41.7 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 8.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 11-20; n=68,1,12,47,6,134 | 11.9 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 2-5; n=71,5,14,44,3,137 | 17.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 2-5; n=68,1,12,47,6,134 | 23.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 0-1; n=68,1,12,47,6,134 | 53.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 6-10; n=71,5,14,44,3,137 | 15.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 21-30; n=73,3,15,61,8,160 | 2.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 11-20; n=82,5,15,74,12,188 | 11.2 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 11-20; n=71,5,14,44,3,137 | 7.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 11-20; n=73,3,15,61,8,160 | 10.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 6-10; n=73,3,15,61,8,160 | 16.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 21-30; n=71,5,14,44,3,137 | 0.7 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 2-5; n=73,3,15,61,8,160 | 28.8 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 0-1; n=80,5,15,70,12,182 | 4.9 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 0-1; n=82,5,15,74,12,188 | 52.7 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: score 0-1; n=73,3,15,61,8,160 | 42.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 21-30; n=80,5,15,70,12,182 | 14.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 2-5; n=82,5,15,74,12,188 | 16.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 11-20; n=80,5,15,70,12,182 | 46.2 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 21-30; n=82,5,15,74,12,188 | 2.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: score 6-10; n=82,5,15,74,12,188 | 17.6 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 6-10; n=80,5,15,70,12,182 | 22.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: score 2-5; n=80,5,15,70,12,182 | 12.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 21-30; n=68,1,12,47,6,134 | 1.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: score 0-1; n=71,5,14,44,3,137 | 59.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: score 6-10; n=68,1,12,47,6,134 | 10.4 percentage of participants |
Secondary
Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status
Clinical psoriasis evaluations by the investigator of percentage of affected BSA. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 7.67 percentage of affected BSA | Standard Deviation 9.33 |
| Participants Treated With Adalimumab | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 2.03 percentage of affected BSA | Standard Deviation 3.06 |
| Participants Treated With Adalimumab | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 1.71 percentage of affected BSA | Standard Deviation 2.39 |
| Participants Treated With Adalimumab | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 21.92 percentage of affected BSA | Standard Deviation 15.02 |
| Participants Treated With Adalimumab | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 2.83 percentage of affected BSA | Standard Deviation 3.56 |
| Participants Treated With Adalimumab: Early Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 9.80 percentage of affected BSA | Standard Deviation 6.61 |
| Participants Treated With Adalimumab: Early Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 31.00 percentage of affected BSA | — |
| Participants Treated With Adalimumab: Early Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 1.67 percentage of affected BSA | Standard Deviation 2.89 |
| Participants Treated With Adalimumab: Early Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 9.80 percentage of affected BSA | Standard Deviation 6.61 |
| Participants Treated With Adalimumab: Early Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 24.80 percentage of affected BSA | Standard Deviation 23.19 |
| Participants Treated With Adalimumab: Late Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 2.25 percentage of affected BSA | Standard Deviation 2.14 |
| Participants Treated With Adalimumab: Late Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 4.34 percentage of affected BSA | Standard Deviation 4.75 |
| Participants Treated With Adalimumab: Late Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 18.25 percentage of affected BSA | Standard Deviation 10.46 |
| Participants Treated With Adalimumab: Late Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 4.89 percentage of affected BSA | Standard Deviation 5.29 |
| Participants Treated With Adalimumab: Late Intermittent | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 4.88 percentage of affected BSA | Standard Deviation 5.48 |
| Participants Treated With Adalimumab: Permanently Discontinued | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 9.09 percentage of affected BSA | Standard Deviation 13.44 |
| Participants Treated With Adalimumab: Permanently Discontinued | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 22.02 percentage of affected BSA | Standard Deviation 15.54 |
| Participants Treated With Adalimumab: Permanently Discontinued | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 11.33 percentage of affected BSA | Standard Deviation 13.57 |
| Participants Treated With Adalimumab: Permanently Discontinued | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 6.42 percentage of affected BSA | Standard Deviation 7.5 |
| Participants Treated With Adalimumab: Permanently Discontinued | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 4.82 percentage of affected BSA | Standard Deviation 6.73 |
| Participants Treated With Adalimumab: Other | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 5.51 percentage of affected BSA | Standard Deviation 5.27 |
| Participants Treated With Adalimumab: Other | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 15.16 percentage of affected BSA | Standard Deviation 20.73 |
| Participants Treated With Adalimumab: Other | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 4.44 percentage of affected BSA | Standard Deviation 4.93 |
| Participants Treated With Adalimumab: Other | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 1.00 percentage of affected BSA | — |
| Participants Treated With Adalimumab: Other | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 23.95 percentage of affected BSA | Standard Deviation 18.25 |
| Participants Treated With Adalimumab: All Participants | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=78, 5, 15, 45, 1, 144 | 3.29 percentage of affected BSA | Standard Deviation 5.01 |
| Participants Treated With Adalimumab: All Participants | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=73, 1, 12, 54, 9, 149 | 5.34 percentage of affected BSA | Standard Deviation 9.27 |
| Participants Treated With Adalimumab: All Participants | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=79, 3, 15, 66, 10, 173 | 9.11 percentage of affected BSA | Standard Deviation 11.89 |
| Participants Treated With Adalimumab: All Participants | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=84, 5, 16, 71, 11, 187 | 21.84 percentage of affected BSA | Standard Deviation 15.21 |
| Participants Treated With Adalimumab: All Participants | Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status | Last Observation; n=84, 5, 16, 74, 12, 191 | 4.39 percentage of affected BSA | Standard Deviation 5.95 |
Secondary
PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status
Percentage of participants who achieved ≥ 50%, 75%, 90% or 100% reduction (improvement) from Baseline in PASI score (PASI50, PASI75, PASI90, PASI100). Four anatomic sites (head, upper extremities, trunk, and lower extremities) were assessed for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination. The severity of each sign was assessed using a 5-point scale: 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. PASI percentage improvement=100\*(PASI score at Baseline - score at follow-up visit) / PASI score at Baseline. For the purpose of analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based on the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 84.4 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 85.5 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 94.8 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 5.3 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 31.9 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 95.0 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 83.8 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 37.5 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 63.8 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 97.1 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 85.5 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 39.0 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 66.2 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 64.5 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 26.3 percentage of participants |
| Participants Treated With Adalimumab | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 65.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 60.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 60.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 50.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 50.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 73.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 30.8 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 31.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 50.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 23.1 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 30.8 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 53.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 13.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 75.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 76.9 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 31.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 75.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 8.5 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 52.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 25.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 6.9 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 13.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 15.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 7.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 64.6 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 68.5 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 40.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 24.1 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 87.2 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 63.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 35.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 34.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 80.6 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 12.5 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 62.5 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 55.6 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 45.5 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 72.7 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Other | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 9.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: = 100%; n=80, 5, 16, 72, 11, 184 | 20.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 50%; n=76, 3, 16, 65, 9, 169 | 77.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 75%; n=76, 3, 16, 65, 9, 169 | 53.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: ≥ 90%; n=76, 3, 16, 65, 9, 169 | 21.9 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: = 100%; n=76, 3, 16, 65, 9, 169 | 7.7 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 50%; n=69, 2, 13, 54, 8, 146 | 84.2 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 75%; n=69, 2, 13, 54, 8, 146 | 62.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: ≥ 90%; n=69, 2, 13, 54, 8, 146 | 42.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: = 100%; n=69, 2, 13, 54, 8, 146 | 21.9 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 50%; n=77, 5, 15, 47, 3, 147 | 88.4 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 75%; n=77, 5, 15, 47, 3, 147 | 72.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: ≥ 90%; n=77, 5, 15, 47, 3, 147 | 49.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: = 100%; n=77, 5, 15, 47, 3, 147 | 24.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 50%; n=80, 5, 16, 72, 11, 184 | 85.3 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 75%; n=80, 5, 16, 72, 11, 184 | 65.2 percentage of participants |
| Participants Treated With Adalimumab: All Participants | PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation: ≥ 90%; n=80, 5, 16, 72, 11, 184 | 41.3 percentage of participants |
Secondary
Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status
The PGA was an evaluation of a participant's psoriasis on a 6-point scale: clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5), which were then regrouped into the 2 categories Clear/Minimal or Mild/Moderate/Severe/Very Severe (M/Md/S/VS), and presented as the percentage of participants in each. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (obs.; up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 41.0 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 59.0 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 22.6 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 77.4 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 22.2 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 77.8 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 98.8 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 1.2 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 21.9 percentage of participants |
| Participants Treated With Adalimumab | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 78.1 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Early Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 56.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 53.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 33.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 43.8 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 66.7 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 43.8 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 56.3 percentage of participants |
| Participants Treated With Adalimumab: Late Intermittent | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 46.7 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 36.2 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 63.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 67.6 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 32.4 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 64.8 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 35.2 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 71.2 percentage of participants |
| Participants Treated With Adalimumab: Permanently Discontinued | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 28.8 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 60.0 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 22.2 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 77.8 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 0.0 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 83.3 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 16.7 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 40.0 percentage of participants |
| Participants Treated With Adalimumab: Other | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 100.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: M/Md/S/VS; n=73,1,12,54,9,149 | 45.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: M/Md/S/VS; n=84,5,16,74,12,191 | 48.7 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: M/Md/S/VS; n=82,5,16,73,12,188 | 99.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: Clear/Minimal; n=78,3,16,66,10,173 | 45.1 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months: Clear/Minimal; n=73,1,12,54,9,149 | 55.0 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: Clear/Minimal; n=81,5,15,47,1,149 | 58.4 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months: M/Md/S/VS; n=78,3,16,66,10,173 | 54.9 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months: M/Md/S/VS; n=81,5,15,47,1,149 | 41.6 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline: Clear/Minimal; n=82,5,16,73,12,188 | 0.5 percentage of participants |
| Participants Treated With Adalimumab: All Participants | Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last obs.: Clear/Minimal; n=84,5,16,74,12,191 | 51.3 percentage of participants |
Secondary
Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status
Four anatomic sites (head, upper extremities, trunk, and lower extremities) were assessed with PASI for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination. The severity of each sign was assessed using a 5-point scale: 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. PASI percentage improvement=100\*(PASI score at Baseline - score at follow-up visit) / PASI score at Baseline. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at Baseline and given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 89.28 percentage improvement | Standard Deviation 13.73 |
| Participants Treated With Adalimumab | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 88.27 percentage improvement | Standard Deviation 17.06 |
| Participants Treated With Adalimumab | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 88.52 percentage improvement | Standard Deviation 17.06 |
| Participants Treated With Adalimumab | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 74.15 percentage improvement | Standard Deviation 27.06 |
| Participants Treated With Adalimumab: Early Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 95.69 percentage improvement | Standard Deviation 7.46 |
| Participants Treated With Adalimumab: Early Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 33.00 percentage improvement | Standard Deviation 65.69 |
| Participants Treated With Adalimumab: Early Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 42.46 percentage improvement | Standard Deviation 45 |
| Participants Treated With Adalimumab: Early Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 42.46 percentage improvement | Standard Deviation 45 |
| Participants Treated With Adalimumab: Late Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 82.25 percentage improvement | Standard Deviation 13.78 |
| Participants Treated With Adalimumab: Late Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 67.55 percentage improvement | Standard Deviation 26.79 |
| Participants Treated With Adalimumab: Late Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 69.82 percentage improvement | Standard Deviation 28.62 |
| Participants Treated With Adalimumab: Late Intermittent | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 69.99 percentage improvement | Standard Deviation 27.66 |
| Participants Treated With Adalimumab: Permanently Discontinued | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 75.93 percentage improvement | Standard Deviation 26.26 |
| Participants Treated With Adalimumab: Permanently Discontinued | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 67.63 percentage improvement | Standard Deviation 32.36 |
| Participants Treated With Adalimumab: Permanently Discontinued | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 52.35 percentage improvement | Standard Deviation 62.07 |
| Participants Treated With Adalimumab: Permanently Discontinued | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 49.96 percentage improvement | Standard Deviation 43.34 |
| Participants Treated With Adalimumab: Other | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 36.41 percentage improvement | Standard Deviation 58.03 |
| Participants Treated With Adalimumab: Other | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 77.39 percentage improvement | Standard Deviation 12.15 |
| Participants Treated With Adalimumab: Other | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 56.70 percentage improvement | Standard Deviation 24.05 |
| Participants Treated With Adalimumab: Other | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 57.46 percentage improvement | Standard Deviation 38.94 |
| Participants Treated With Adalimumab: All Participants | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=80, 5, 16, 72, 11, 184 | 75.52 percentage improvement | Standard Deviation 29.48 |
| Participants Treated With Adalimumab: All Participants | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 24 months; n=77, 5, 15, 47, 3, 147 | 79.96 percentage improvement | Standard Deviation 26.28 |
| Participants Treated With Adalimumab: All Participants | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 12 months; n=69, 2, 13, 54, 8, 146 | 72.26 percentage improvement | Standard Deviation 43.62 |
| Participants Treated With Adalimumab: All Participants | Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status | TW 3 months; n=76, 3, 16, 65, 9, 169 | 65.06 percentage improvement | Standard Deviation 35.52 |
Secondary
Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status
Absenteeism, presented as the mean percentage of work time missed due to psoriasis (as reported on the WPAI), and calculated as: 100\*number of hours of work missed due to psoriasis / (number of hours of work missed due to psoriasis + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with assessment at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.21 percentage of work time missed | Standard Deviation 1.39 |
| Participants Treated With Adalimumab | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 3.05 percentage of work time missed | Standard Deviation 14.92 |
| Participants Treated With Adalimumab | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 25.00 percentage of work time missed | Standard Deviation 50 |
| Participants Treated With Adalimumab: Early Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 0.00 percentage of work time missed | — |
| Participants Treated With Adalimumab: Late Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Permanently Discontinued | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 0.00 percentage of work time missed | Standard Deviation 0 |
| Participants Treated With Adalimumab: Permanently Discontinued | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 2.92 percentage of work time missed | Standard Deviation 16.9 |
| Participants Treated With Adalimumab: Permanently Discontinued | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.81 percentage of work time missed | Standard Deviation 4.49 |
| Participants Treated With Adalimumab: Permanently Discontinued | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 2.27 percentage of work time missed | Standard Deviation 10.66 |
| Participants Treated With Adalimumab: Permanently Discontinued | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 2.66 percentage of work time missed | Standard Deviation 10.73 |
| Participants Treated With Adalimumab: Other | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | NA percentage of work time missed | — |
| Participants Treated With Adalimumab: Other | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 1.00 percentage of work time missed | Standard Deviation 2.27 |
| Participants Treated With Adalimumab: Other | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 6.62 percentage of work time missed | Standard Deviation 16.1 |
| Participants Treated With Adalimumab: Other | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.86 percentage of work time missed | Standard Deviation 2.11 |
| Participants Treated With Adalimumab: Other | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 17.78 percentage of work time missed | Standard Deviation 30.79 |
| Participants Treated With Adalimumab: All Participants | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=48, 4, 9, 35, 10, 106 | 3.38 percentage of work time missed | Standard Deviation 16.83 |
| Participants Treated With Adalimumab: All Participants | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 0.64 percentage of work time missed | Standard Deviation 5.66 |
| Participants Treated With Adalimumab: All Participants | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=43, 2, 7, 31, 6, 89 | 0.44 percentage of work time missed | Standard Deviation 2.85 |
| Participants Treated With Adalimumab: All Participants | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 1.49 percentage of work time missed | Standard Deviation 7.98 |
| Participants Treated With Adalimumab: All Participants | Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 0.72 percentage of work time missed | Standard Deviation 6.2 |
Secondary
WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status
Activity impairment due to psoriasis (the extent to which psoriasis affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 4.53 percentage of activity impairment | Standard Deviation 13.68 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 8.36 percentage of activity impairment | Standard Deviation 16.35 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 33.38 percentage of activity impairment | Standard Deviation 28.05 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 4.02 percentage of activity impairment | Standard Deviation 12.26 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 5.56 percentage of activity impairment | Standard Deviation 13.65 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 0.00 percentage of activity impairment | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 32.00 percentage of activity impairment | Standard Deviation 39.62 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 28.00 percentage of activity impairment | Standard Deviation 31.14 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 32.00 percentage of activity impairment | Standard Deviation 39.62 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 40.00 percentage of activity impairment | — |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 8.46 percentage of activity impairment | Standard Deviation 14.05 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 18.57 percentage of activity impairment | Standard Deviation 19.94 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 17.33 percentage of activity impairment | Standard Deviation 19.81 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 12.73 percentage of activity impairment | Standard Deviation 16.18 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 32.31 percentage of activity impairment | Standard Deviation 23.86 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 17.91 percentage of activity impairment | Standard Deviation 24.35 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 34.92 percentage of activity impairment | Standard Deviation 26.35 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 20.53 percentage of activity impairment | Standard Deviation 28.37 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 12.00 percentage of activity impairment | Standard Deviation 18.43 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 17.40 percentage of activity impairment | Standard Deviation 25.61 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 25.00 percentage of activity impairment | Standard Deviation 35.36 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 35.00 percentage of activity impairment | Standard Deviation 20.68 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 21.00 percentage of activity impairment | Standard Deviation 29.98 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 40.00 percentage of activity impairment | Standard Deviation 41.63 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 10.00 percentage of activity impairment | Standard Deviation 14.14 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=74, 5, 13, 65, 10, 167 | 33.83 percentage of activity impairment | Standard Deviation 26.52 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=64, 5, 14, 40, 2, 125 | 9.92 percentage of activity impairment | Standard Deviation 18.77 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=61, 3, 13, 57, 7, 141 | 14.68 percentage of activity impairment | Standard Deviation 24.48 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=82, 5, 15, 73, 10, 185 | 12.05 percentage of activity impairment | Standard Deviation 22.09 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=63, 1, 11, 43, 5, 123 | 10.98 percentage of activity impairment | Standard Deviation 19.14 |
Secondary
WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status
Presenteeism (the extent to which psoriasis decreased productivity) is presented as the mean percentage of impairment while working due to psoriasis, and calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any follow-up data were available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | 2.61 percentage of impairment while working | Standard Deviation 8.01 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 6.74 percentage of impairment while working | Standard Deviation 18.26 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 22.50 percentage of impairment while working | Standard Deviation 25.81 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 3.33 percentage of impairment while working | Standard Deviation 8.77 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 4.22 percentage of impairment while working | Standard Deviation 12.34 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 0.00 percentage of impairment while working | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | 12.50 percentage of impairment while working | Standard Deviation 25 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 0.00 percentage of impairment while working | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 12.50 percentage of impairment while working | Standard Deviation 25 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 60.00 percentage of impairment while working | — |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 0.00 percentage of impairment while working | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | 16.36 percentage of impairment while working | Standard Deviation 21.57 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 16.36 percentage of impairment while working | Standard Deviation 21.57 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 5.00 percentage of impairment while working | Standard Deviation 8.37 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 11.11 percentage of impairment while working | Standard Deviation 11.67 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 9.26 percentage of impairment while working | Standard Deviation 17.3 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 18.51 percentage of impairment while working | Standard Deviation 19.82 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 6.18 percentage of impairment while working | Standard Deviation 13.71 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | 5.42 percentage of impairment while working | Standard Deviation 10.21 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 9.08 percentage of impairment while working | Standard Deviation 19.03 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | NA percentage of impairment while working | — |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 30.00 percentage of impairment while working | Standard Deviation 19.44 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 20.91 percentage of impairment while working | Standard Deviation 27.37 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 28.33 percentage of impairment while working | Standard Deviation 38.17 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 10.00 percentage of impairment while working | Standard Deviation 17.32 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=52, 3, 9, 37, 10, 111 | 20.32 percentage of impairment while working | Standard Deviation 22.55 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=46, 4, 11, 24, 0, 85 | 5.65 percentage of impairment while working | Standard Deviation 12.77 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=46, 2, 8, 34, 6, 96 | 7.19 percentage of impairment while working | Standard Deviation 18.28 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 49, 11, 135 | 8.19 percentage of impairment while working | Standard Deviation 17.27 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=45, 1, 6, 27, 3, 82 | 6.83 percentage of impairment while working | Standard Deviation 15.22 |
Secondary
WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status
The mean percentage of TWPI due to psoriasis (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which psoriasis decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to psoriasis + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. For the purpose of the analysis of the evolution of parameters over time, follow-up visits were classified into time-windows (TWs), based upon the number of days between onset of adalimumab treatment and the date of each subsequent visit: TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730).
Time frame: Baseline, TW 3 months=period between Day 1 and 137 (target, Day 91); TW 12 months=period between Day 275 and 456 (target, Day 365); TW 24 months=period starting on Day 640 (target Day 730); last observation (up to 24 months)
Population: ITT set: all participants enrolled in the study who received at least 1 dose of adalimumab, and for whom any data follow-up were available; n=number of participants with an assessment at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 2.20 percentage of TWPI | Standard Deviation 7.25 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 6.65 percentage of TWPI | Standard Deviation 18.82 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 21.29 percentage of TWPI | Standard Deviation 25.24 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 3.83 percentage of TWPI | Standard Deviation 10.1 |
| Participants Treated With Adalimumab | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 3.85 percentage of TWPI | Standard Deviation 11.84 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 0.00 percentage of TWPI | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 12.50 percentage of TWPI | Standard Deviation 25 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 0.00 percentage of TWPI | Standard Deviation 0 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 12.50 percentage of TWPI | Standard Deviation 25 |
| Participants Treated With Adalimumab: Early Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 60.00 percentage of TWPI | — |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 0.00 percentage of TWPI | Standard Deviation 0 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 16.36 percentage of TWPI | Standard Deviation 21.57 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 16.36 percentage of TWPI | Standard Deviation 21.57 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 2.00 percentage of TWPI | Standard Deviation 4.47 |
| Participants Treated With Adalimumab: Late Intermittent | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 11.11 percentage of TWPI | Standard Deviation 11.67 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 9.62 percentage of TWPI | Standard Deviation 17.55 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 16.78 percentage of TWPI | Standard Deviation 16.71 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 6.69 percentage of TWPI | Standard Deviation 15.4 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 7.27 percentage of TWPI | Standard Deviation 13.86 |
| Participants Treated With Adalimumab: Permanently Discontinued | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 9.95 percentage of TWPI | Standard Deviation 19.14 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | NA percentage of TWPI | — |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 30.64 percentage of TWPI | Standard Deviation 19.42 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 26.58 percentage of TWPI | Standard Deviation 28.68 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 28.42 percentage of TWPI | Standard Deviation 38.33 |
| Participants Treated With Adalimumab: Other | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 27.78 percentage of TWPI | Standard Deviation 26.74 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Baseline; n=47, 3, 9, 34, 10, 103 | 19.20 percentage of TWPI | Standard Deviation 21.33 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 24 months; n=41, 4, 11, 22, 0, 78 | 6.15 percentage of TWPI | Standard Deviation 13.79 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 3 months; n=42, 2, 7, 31, 6, 88 | 7.47 percentage of TWPI | Standard Deviation 19.23 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Last observation; n=60, 4, 11, 47, 11, 133 | 9.17 percentage of TWPI | Standard Deviation 18.11 |
| Participants Treated With Adalimumab: All Participants | WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status | Time-window 12 months; n=39, 1, 5, 26, 3, 74 | 7.48 percentage of TWPI | Standard Deviation 16.26 |